Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events. Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more

Produk Detail:

  • Author : Giuseppe Tridente
  • Publisher : Academic Press
  • Pages : 736 pages
  • ISBN : 0128094451
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors
  • Author : Giuseppe Tridente
  • Publisher : Academic Press
  • Release : 08 May 2017
GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s)

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 21 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic,

Cardio-Oncology

Cardio-Oncology
  • Author : Roberta A. Gottlieb,Puja K Mehta
  • Publisher : Academic Press
  • Release : 26 November 2016
GET THIS BOOKCardio-Oncology

Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well

FDA's Drug Review Process and the Package Label

FDA's Drug Review Process and the Package Label
  • Author : Tom Brody
  • Publisher : Academic Press
  • Release : 13 December 2017
GET THIS BOOKFDA's Drug Review Process and the Package Label

FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data

Renal Disease in Cancer Patients

Renal Disease in Cancer Patients
  • Author : Kevin W. Finkel,Scott C. Howard
  • Publisher : Academic Press
  • Release : 02 September 2013
GET THIS BOOKRenal Disease in Cancer Patients

Renal Disease in Cancer Patients is a translational reference detailing the nephrological problems unique to patients with cancer in an organized and authoritative fashion. This book provides a common language for nephrologists, oncologists, hematologists, and other clinicians who treat cancer patients, to discuss the development of renal diseases in the context of cancer and options for their optimum diagnosis, management, and treatment. With the advent of better supportive care and the era of personalized medicine, patients with cancer are living

SITC’s Guide to Managing Immunotherapy Toxicity

SITC’s Guide to Managing Immunotherapy Toxicity
  • Author : Marc S. Ernstoff, MD,Igor Puzanov, MD, MSCI, FACP,Caroline Robert, MD, PhD,Adi M. Diab, MD,Peter M. Hersey, MD, PhD
  • Publisher : Springer Publishing Company
  • Release : 15 March 2019
GET THIS BOOKSITC’s Guide to Managing Immunotherapy Toxicity

The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured

Cancer Drug Design and Discovery

Cancer Drug Design and Discovery
  • Author : Stephen Neidle
  • Publisher : Elsevier
  • Release : 28 April 2011
GET THIS BOOKCancer Drug Design and Discovery

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing

Next Generation Kinase Inhibitors

Next Generation Kinase Inhibitors
  • Author : Paul Shapiro
  • Publisher : Springer Nature
  • Release : 14 July 2020
GET THIS BOOKNext Generation Kinase Inhibitors

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated

Immunotherapy of Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma
  • Author : Tim F. Greten
  • Publisher : Springer
  • Release : 04 October 2017
GET THIS BOOKImmunotherapy of Hepatocellular Carcinoma

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of

Anti-fibrotic Drug Discovery

Anti-fibrotic Drug Discovery
  • Author : Jehrod Brenneman,Malliga R Iyer
  • Publisher : Royal Society of Chemistry
  • Release : 17 February 2020
GET THIS BOOKAnti-fibrotic Drug Discovery

Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book

Protein Kinase CK2

Protein Kinase CK2
  • Author : Lorenzo A. Pinna
  • Publisher : John Wiley & Sons
  • Release : 14 January 2013
GET THIS BOOKProtein Kinase CK2

The importance of CK2 in cancer and other diseases has generated a significant amount of literature on the protein, and an international community of CK2 researchers. The International Union of Biochemistry and Molecular Biology (IUMBMB) sponsors periodic international conferences on CK2, making the protein a natural topic for a Wiley-IUBMB publication. Protein Kinase CK2 will deal with structural aspects underlying the constitutive activity of CK2, its specific susceptibility to pharmacological inhibition and its extraordinary pleiotropy. In the second part the

Small Molecules in Oncology

Small Molecules in Oncology
  • Author : Uwe M. Martens
  • Publisher : Springer Science & Business Media
  • Release : 14 January 2010
GET THIS BOOKSmall Molecules in Oncology

Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of